Gilead Sciences Expands Collaboration with Galapagos
On July 14, Gilead Sciences announced that it will expand its collaboration with Galapagos (GLPG).
What’s behind the Dismal Performance of NBQAX?
NBQAX has had a terrible 2016 so far. Among its top invested sectors, information technology has been almost inconsequential to its performance.
AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494
Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.
Why Has the Nuveen International Growth Fund Stumbled in YTD 2016?
Through June 17, the Nuveen International Growth Fund – Class A (NBQAX) has figured among the bottom three funds in its peer group of 12 funds.